208 related articles for article (PubMed ID: 35186740)
1. A Risk Model Composed of Complete Blood Count,
Wang L; Yuan L; Du X; Zhou K; Yang Y; Qin Q; Yang L; Xiang Y; Qu X; Liu H; Qin X; Liu C
Front Oncol; 2022; 12():800786. PubMed ID: 35186740
[TBL] [Abstract][Full Text] [Related]
2. Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma.
Feng Y; Liu Y; Zhong M; Wang L
Front Oncol; 2021; 11():618694. PubMed ID: 33842320
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era.
Li Q; Yu L; Yang P; Hu Q
Cancer Manag Res; 2021; 13():6799-6810. PubMed ID: 34512020
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
7.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
8. Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.
Yang Y; Wang C; Wang D; Cui L; Li N; Lian H; Ma H; Zhao Y; Zhang L; Liu W; Wang Y; Wu W; Zhang R; Li Z; Wang T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2517-2527. PubMed ID: 34595543
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
[TBL] [Abstract][Full Text] [Related]
10. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Inflammatory and Nutritional Markers for Patients With Early-Stage Poorly-to Moderately-Differentiated Cervical Squamous Cell Carcinoma.
Guo J; Lv W; Wang Z; Shang Y; Yang F; Zhang X; Xiao K; Zhang S; Pan X; Han Y; Zong L; Hu W
Cancer Control; 2023; 30():10732748221148913. PubMed ID: 36599103
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Systemic Inflammatory Markers in Patients Undergoing Surgical Resection for Oral Squamous Cell Carcinoma.
Cho U; Sung YE; Kim MS; Lee YS
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740290
[TBL] [Abstract][Full Text] [Related]
13. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients.
Shi X; Li H; Xu Y; Nyalali AMK; Li F
Neurol Sci; 2022 Sep; 43(9):5523-5531. PubMed ID: 35606674
[TBL] [Abstract][Full Text] [Related]
15. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Inflammatory Biomarkers as Prognostic Indicator in Salivary Gland Malignancy.
Abbate V; Barone S; Troise S; Laface C; Bonavolontà P; Pacella D; Salzano G; Iaconetta G; Califano L; Dell'Aversana Orabona G
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497416
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of systemic immune and inflammatory biomarkers in hidradenitis suppurativa.
Utlu Z
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9267-9272. PubMed ID: 37843340
[TBL] [Abstract][Full Text] [Related]
19. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
